KCNQ5/Q3 channels are identified as a molecular target for the anticonvulsant retigabine, suggesting their activation may contribute to its therapeutic activity.
Answers are grounded in this paper and cite their sources.
Suggests KCNQ5/Q3 activation contributes to retigabine anticonvulsant effects; leaves open in vivo validation and clinical translation.
Heteromeric KCNQ5/Q3 channels were stably expressed in Chinese Hamster ovary cells and characterized using the whole cell voltage-clamp technique. KCNQ5/Q3 channels were activated by the novel anticonvulsant, retigabine (EC(50) 1.4 microM) by a mechanism that involved drug-induced, leftward shifts in the voltage-dependence of channel activation (-31.8 mV by 30 microM retigabine). KCNQ5/Q3 channels were inhibited by linopirdine (IC(50) 7.7 microM) and barium (IC(50) 0.46 mM), at concentrations similar to those required to inhibit native M-currents. These findings identify KCNQ5/Q3 channels as a molecular target for retigabine and raise the possibility that activation of KCNQ5/Q3 channels may be responsible for some of the anti-convulsant activity of this agent. Furthermore, the sensitivity of KCNQ5/Q3 channels to linopirdine supports the possibility that potassium channels comprised of KCNQ5 and KCNQ3 may make a contribution to native M-currents.
No takes yet. Share an insight, caveat, or question.
Wickenden et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: